Table 5.

Multivariate analysis, Part A: progression free survival (PFS) variables. Part B: survival (OS) variables

Variables (number of patients)	HR (95% CI)	P value
Part A: progression free survival
Third line treatment
Systemic therapy control group (n = 19)	2.182 (1.132–4.204)	0.020
HPP/target therapy group (n = 43)
Yamada’ s modified classification (Yamada et al. 2001)
Localized* (n = 13)
Sacral (n = 37)	2.569 (1.061–6.222)	0.036
Lateral (n = 12)	8.703 (2.535–29.872)	0.001
Other sites of metastases
Yes (n = 37)	0.783 (0.398–1.542)	0.481 (ns)
Not (n = 25)
ECOG
1 (n = 10)
2 (n = 12)
3 (n = 40)	1.492 (1.003–2.220)	0.048
Part B: survival
Third line treatment
Systemic therapy control group (n = 19)	4.393 (1.992–9.684)	0.001
HPP/target therapy group (n = 43)
Age
≤ 60 (n = 29)	2.360 (1.317–4.229)	0.004
> 60 (n = 33)
Yamada’ s modified classification (Yamada et al. 2001)
Localized* (n = 13)
Sacral (n = 37)	5.306 (1.861–15.126)	0.002
Lateral (n = 12)	11.086 (2.847–43.155)	0.001
Other sites of metastases
Yes (n = 37)	1.487 (0.916–2.413)	0.108 (ns)
Not (n = 25)
ECOG
1 (n = 10)
2 (n = 12)
3 (n = 40)	0.827 (0.417–1.636)	0.586 (ns)

* Including also cases with invasion of uterus, vagina, bladder, prostate, and seminal vesicles